Alentemol (INN) (developmental code name U-66444B), or alentamol, is a selective dopamine autoreceptor agonist described as an antipsychotic, which was never marketed.[1][2]

Alentemol
Names
IUPAC name
2-(Dipropylamino)-2,3-dihydro-1H-phenalen-5-ol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C19H25NO/c1-3-8-20(9-4-2)17-10-14-6-5-7-15-12-18(21)13-16(11-17)19(14)15/h5-7,12-13,17,21H,3-4,8-11H2,1-2H3
    Key: TWUJBHBRYYTEDL-UHFFFAOYSA-N
  • InChI=1/C19H25NO/c1-3-8-20(9-4-2)17-10-14-6-5-7-15-12-18(21)13-16(11-17)19(14)15/h5-7,12-13,17,21H,3-4,8-11H2,1-2H3
    Key: TWUJBHBRYYTEDL-UHFFFAOYAC
  • CCCN(CCC)C1CC2=CC=CC3=CC(=CC(=C23)C1)O
Properties
C19H25NO
Molar mass 283.415 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

References

edit
  1. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 143–. ISBN 978-0-8155-1856-3.
  2. ^ A.F. Casy (11 November 2013). The Steric Factor in Medicinal Chemistry: Dissymmetric Probes of Pharmacological Receptors. Springer Science & Business Media. pp. 178–. ISBN 978-1-4899-2397-4.